<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="sub-topic" /><meta name="keywords" content="Pain: palliative care; Paracetamol: pain: palliative care; Analgesics: NSAIDs: palliative care; Metastron (strontium); Analgesics: opioid: palliative care; Codeine: pain: palliative care; Tramadol: pain: palliative care; Morphine: analgesia: palliative care; Hydromorphone: palliative care; Methadone: palliative care; Oxycodone: palliative care; Fentanyl: analgesia: palliative care; Diamorphine: morphine equivalence: intramuscular; Hydromorphone: morphine equivalence; Oxycodone: palliative care: morphine equivalence; Analgesics: opioid: equivalent doses; Morphine: analgesia: palliative care; Analgesics: NSAIDs: palliative care; Morphgesic SR: palliative care; MST Continus: palliative care; Zomorph: palliative care; MXL: palliative care; Pain: palliative care: breakthrough; Oxycodone: palliative care; Levomepromazine: palliative care; Diamorphine: pain: chronic; Morphine: analgesia: palliative care; Oxycodone: palliative care; Fentanyl: analgesia: palliative care; Buprenorphine: palliative care; Fentanyl: analgesia: morphine equivalence; Morphine: analgesia: fentanyl equivalence; Loperamide: palliative care; Hyoscine hydrobromide: palliative care: gastro-intestinal pain; Antacids: palliative care; Domperidone: palliative care; Gabapentin: neuropathic pain: palliative care; Pregabalin: neuropathic pain: palliative care; Ketamine: neuropathic pain: palliative care; Dexamethasone: neuropathic pain, palliative care" /><meta name="IX" content="Pain: palliative care; Paracetamol: pain: palliative care; Analgesics: NSAIDs: palliative care; Metastron (strontium); Analgesics: opioid: palliative care; Codeine: pain: palliative care; Tramadol: pain: palliative care; Morphine: analgesia: palliative care; Hydromorphone: palliative care; Methadone: palliative care; Oxycodone: palliative care; Fentanyl: analgesia: palliative care; Diamorphine: morphine equivalence: intramuscular; Hydromorphone: morphine equivalence; Oxycodone: palliative care: morphine equivalence; Analgesics: opioid: equivalent doses; Morphine: analgesia: palliative care; Analgesics: NSAIDs: palliative care; Morphgesic SR: palliative care; MST Continus: palliative care; Zomorph: palliative care; MXL: palliative care; Pain: palliative care: breakthrough; Oxycodone: palliative care; Levomepromazine: palliative care; Diamorphine: pain: chronic; Morphine: analgesia: palliative care; Oxycodone: palliative care; Fentanyl: analgesia: palliative care; Buprenorphine: palliative care; Fentanyl: analgesia: morphine equivalence; Morphine: analgesia: fentanyl equivalence; Loperamide: palliative care; Hyoscine hydrobromide: palliative care: gastro-intestinal pain; Antacids: palliative care; Domperidone: palliative care; Gabapentin: neuropathic pain: palliative care; Pregabalin: neuropathic pain: palliative care; Ketamine: neuropathic pain: palliative care; Dexamethasone: neuropathic pain, palliative care" /><title>Pain: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="59/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="PHP0-publication-information.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="PHP114-pain.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="PHP114-pain.htm#pB" title="Skip Navigation">Skip Navigation</a><img src="../../images/mylogo.png" alt="BNF.org Free Access" id="pI" /><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=PHP114-pain.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 06 Oct 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF September 2012</a> &gt; <a href="PHP59-guidance-on-prescribing.htm">Guidance on prescribing</a> &gt; <a href="PHP113-prescribing-in-palliative-care.htm">Prescribing in palliative care</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="PHP113-prescribing-in-palliative-care.htm" title="Previous: Prescribing in palliative care">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="PHP120-miscellaneous-conditions.htm" title="Next: Miscellaneous conditions">Next page</a> ►</div></div></div></div><div id="p1"><div id="pB"><h1>Pain</h1><?highlighter on?><div id="pC" class="jN"><div class="cI"><p class="cAE">NICE guidance</p>  <p>For additional information, see NICE clinical guideline 140 (May 2012) <span><a href="http://publications.nice.org.uk/opioids-in-palliative-care-safe-and-effective-prescribing-of-strong-opioids-for-pain-in-palliative-cg140">Opioids in palliative care: safe and effective prescribing of strong opioids for pain in palliative care in adults</a></span>.</p> </div><p>Analgesics are more effective in preventing pain than in the relief of established pain; it is important that they are given regularly.</p><p><a title="monograph: PARACETAMOL" href="PHP2632-paracetamol.htm"><strong>Paracetamol</strong></a> or a <strong>NSAID</strong> (<a title="sub-section: Non-steroidal anti-inflammatory drugs" href="PHP6379-non-steroidal-anti-inflammatory-drugs.htm">section 10.1.1</a>) given regularly will often make the use of opioid analgesics unnecessary. A NSAID may also control the pain of <em>bone secondaries</em>; if necessary, flurbiprofen or indometacin can be given rectally. Radiotherapy, bisphosphonates (<a title=" Bisphosphonates" href="PHP4652-bisphosphonates-and-other-drugs-affecting-bone-metabolism.htm">section 6.6.2</a>), and radioactive isotopes of <strong>strontium</strong> (<em>Metastron</em>® available from GE Healthcare) may also be useful for pain due to bone metastases.</p><p>An opioid analgesic (<a title="BNF:sub-section: Opioid analgesics" href="PHP2667-opioid-analgesics.htm">section 4.7.2</a>) such as <a title="BNF:monograph: CODEINE PHOSPHATE" href="PHP2687-codeine-phosphate.htm"><strong>codeine</strong></a>, alone or in combination with a non-opioid analgesic at adequate dosage, may be helpful in the control of moderate pain if non-opioid analgesics alone are not sufficient. Alternatively, <a title="BNF:monograph: TRAMADOL HYDROCHLORIDE" href="PHP2795-tramadol-hydrochloride.htm"><strong>tramadol</strong></a> can be considered for moderate pain. If these preparations do not control the pain, <a title="BNF:monograph: MORPHINE SALTS" href="PHP2740-morphine-salts.htm"><strong>morphine</strong></a> is the most useful opioid analgesic. Alternatives to morphine, including <a title="BNF:monograph: HYDROMORPHONE HYDROCHLORIDE" href="PHP2727-hydromorphone-hydrochloride.htm"><strong>hydromorphone</strong></a>, <a title="BNF:monograph: METHADONE HYDROCHLORIDE" href="PHP2733-methadone-hydrochloride.htm"><strong>methadone</strong></a>, <a title="BNF:monograph: OXYCODONE HYDROCHLORIDE" href="PHP2766-oxycodone-hydrochloride.htm"><strong>oxycodone</strong></a>, and transdermal <a title="BNF:monograph: FENTANYL" href="PHP2713-fentanyl.htm"><strong>fentanyl</strong></a> (see below) are best initiated by those with experience in palliative care. Initiation of an opioid analgesic should not be delayed by concern over a theoretical likelihood of psychological dependence (addiction).</p><div class="table" id="PHP115"><div class="cAA">Equivalent single doses of opioid analgesics<span></span></div><table class="table" summary="Equivalent single doses of opioid analgesicsAnalgesics: opioid: equivalent doses" cellspacing="0" cellpadding="8" border="0" style="border-collapse: collapse;border-top: 1pt solid ; border-bottom: 1pt solid ; "><colgroup><col /><col /></colgroup><thead><tr><th style="border-bottom: 1pt solid ; " colspan="2">These equivalences are intended <strong>only</strong> as an approximate guide; patients should be carefully monitored after <strong>any</strong> change in medication and dose titration may be required</th></tr><tr><th style="border-bottom: 1pt solid ; ">Analgesic</th><th style="border-bottom: 1pt solid ; ">Dose</th></tr></thead><tbody><tr><td style="">Morphine salts (oral)</td><td style="">10 mg</td></tr><tr><td style="">Diamorphine hydrochloride (intramuscular)</td><td style="">3 mg</td></tr><tr><td style="">Hydromorphone hydrochloride</td><td style="">1.3 mg</td></tr><tr><td style="">Oxycodone (oral)</td><td style="">5 mg</td></tr></tbody></table></div><div id="PHP117"><h2>Oral route</h2><p><a title="BNF:monograph: MORPHINE SALTS" href="PHP2740-morphine-salts.htm">Morphine</a> is given <em>by mouth</em> as an oral solution or as standard (‘immediate release’) tablets regularly every 4 hours, the initial dose depending largely on the patient's previous treatment. A dose of 5–10 mg is enough to replace a weaker analgesic (such as paracetamol), but 10–20 mg or more is required to replace a strong one (comparable to morphine itself). If the first dose of morphine is no more effective than the previous analgesic, the next dose should be increased by 30–50%, the aim being to choose the lowest dose that prevents pain. The dose should be adjusted with careful assessment of the pain, and the use of adjuvant analgesics (such as NSAIDs) should also be considered. Although morphine in a dose of 5–20 mg is usually adequate there should be no hesitation in increasing it stepwise according to response to 100 mg or occasionally up to 500 mg or higher if necessary. It may be possible to omit the overnight dose if double the usual dose is given at bedtime.</p><p>When the pain is controlled and the patient's 24-hour morphine requirement is established, the daily dose can be given as a <em>modified-release preparation</em> in a single dose or in two divided doses.</p><p>Preparations suitable for twice-daily administration include <a title="BNF:preparation: Morphgesic® SR" href="PHP2751-morphgesic-sr.htm#PHP2751-morphgesic-sr"><em>Morphgesic</em>® <em>SR</em></a> tablets, <a title="BNF:preparation: MST Continus®" href="PHP2752-mst-continus.htm#PHP2752-mst-continus"><em>MST Continus</em>®</a> tablets or suspension, and <a title="BNF:preparation: Zomorph®" href="PHP2753-zomorph.htm#PHP2753-zomorph"><em>Zomorph</em>®</a> capsules. <a title="BNF:preparation: MXL®" href="PHP2755-mxl.htm#PHP2755-mxl"><em>MXL</em>®</a> capsules allow administration of the total daily morphine requirement as a single dose.</p><p>The starting dose of modified-release morphine preparations designed for twice daily administration is usually 10–20 mg every 12 hours if no other analgesic (or only paracetamol) has been taken previously, but to replace a weaker opioid analgesic (such as co-codamol) the starting dose is usually 20–30 mg every 12 hours. Increments should be made to the dose, not to the frequency of administration, which should remain at every 12 hours.</p><p>The effective dose of modified-release preparations can alternatively be determined by giving the oral solution of morphine every 4 hours in increasing doses until the pain has been controlled, and then transferring the patient to the same total 24-hour dose of morphine given as the modified-release preparation (divided into two portions for 12-hourly administration). The first dose of the modified-release preparation is given with, or within 4 hours of, the last dose of the oral solution. The patient should be monitored closely for treatment efficacy and side-effects.</p><p>If pain occurs between regular doses of morphine (‘breakthrough pain’), an additional dose (‘rescue dose’) should be given. An additional dose should also be given 30 minutes before an activity that causes pain (e.g. wound dressing). Morphine, as oral solution or standard formulation tablets, should be prescribed for breakthrough pain. The standard dose of a strong opioid for breakthrough pain is usually one-tenth to one-sixth of the regular 24 hour total daily dose, repeated every 4 hours, or as necessary (review pain management if analgesic required more frequently). Each patient should be assessed on an individual basis. Fentanyl lozenges are also licensed for breakthrough pain.</p><p><a title="monograph: OXYCODONE HYDROCHLORIDE" href="PHP2766-oxycodone-hydrochloride.htm"><strong>Oxycodone</strong></a> can be used in patients who require an opioid but cannot tolerate morphine. If the patient is already receiving an opioid, oxycodone should be started at a dose equivalent to the current analgesic (see <a title="table: no context" href="PHP114-pain.htm#PHP115">Equivalent Single Doses of Opioid Analgesics table</a>).</p><p><a title="BNF:monograph: LEVOMEPROMAZINE" href="PHP2234-levomepromazine.htm"><strong>Levomepromazine</strong></a> is licensed to treat pain in palliative care. However, such use is reserved for distressed patients with severe pain unresponsive to other measures (seek specialist advice).</p> </div><div><h2>Parenteral route</h2><p>If the patient becomes unable to swallow, the equivalent intramuscular dose of morphine is half the oral solution dose; in the case of the modified-release tablets it is half the total 24-hour dose (which is then divided into 6 portions to be given every 4 hours). <a title="BNF:monograph: DIAMORPHINE HYDROCHLORIDE" href="PHP2699-diamorphine-hydrochloride.htm"><strong>Diamorphine </strong></a>  is preferred for injection because, being more soluble, it can be given in a smaller volume. The equivalent intramuscular (or subcutaneous) dose is approximately a third of the oral dose of morphine. <em>Subcutaneous infusion</em> of diamorphine via continuous infusion device can be useful (for details, see <a title="topic: Syringe drivers" href="PHP130-continuous-infusion-devices.htm">Continuous Infusion Devices</a>).</p><p>If the patient can resume taking medicines by mouth, then oral morphine may be substituted for subcutaneous infusion of diamorphine. See <a title="target-block: Equivalent doses of morphine sulphate" href="PHP130-continuous-infusion-devices.htm#PHP137">table</a> of approximate equivalent doses of morphine and diamorphine. </p></div><div><h2>Rectal route</h2><p><a title="BNF:preparation: Morphine" href="PHP2757-morphine-non-proprietary.htm#PHP2757-morphine-non-proprietary"><strong>Morphine</strong></a> is also available for <em>rectal administration</em> as suppositories; alternatively <a title="BNF:monograph: OXYCODONE HYDROCHLORIDE" href="PHP2766-oxycodone-hydrochloride.htm"><strong>oxycodone</strong></a> suppositories can be obtained on special order.</p></div><div id="PHP118"><h2>Transdermal route</h2><p>Transdermal preparations of fentanyl and buprenorphine are available (<a title=" Opioid analgesics" href="PHP2667-opioid-analgesics.htm">section 4.7.2</a>); they are not suitable for acute pain or in patients whose analgesic requirements are changing rapidly because the long time to steady state prevents rapid titration of the dose. Prescribers should ensure that they are familiar with the correct use of transdermal preparations (see under <a title="BNF:monograph: FENTANYL" href="PHP2713-fentanyl.htm">Fentanyl</a>) because inappropriate use has caused fatalities.</p><p>The following 24-hour doses of morphine <strong>by mouth</strong> are considered to be approximately equivalent to the fentanyl patches shown:</p><ul class="cW"><li><p>Morphine salt 45 mg daily ≡ fentanyl ‘12’ patch</p> </li><li><p>Morphine salt 90 mg daily ≡ fentanyl ‘25’ patch</p> </li><li><p>Morphine salt 180 mg daily ≡ fentanyl ‘50’ patch</p> </li><li><p>Morphine salt 270 mg daily ≡ fentanyl ‘75’ patch</p> </li><li><p>Morphine salt 360 mg daily ≡ fentanyl ‘100’ patch</p> </li></ul><p>Morphine (as oral solution or standard formulation tablets) is given for breakthrough pain.</p></div><div><h2>Gastro-intestinal pain</h2><p>The pain of <em>bowel colic</em> may be reduced by loperamide 2–4 mg 4 times daily. Hyoscine hydrobromide (<a title="monograph: HYOSCINE HYDROBROMIDE" href="PHP2576-hyoscine-hydrobromide.htm">section 4.6</a>) may also be helpful, given sublingually at a dose of 300 micrograms 3 times daily as <em>Kwells</em>® tablets. Subcutaneous injections of hyoscine butylbromide, hyoscine hydrobromide, and glycopyrronium can also be used to treat bowel colic (see below). For doses by subcutaneous infusion, see <a title="target-block: BOWEL COLIC AND EXCESSIVE RESPIRATORY SECRETIONS" href="PHP130-continuous-infusion-devices.htm#PHP131">Bowel Colic and Excessive Respiratory Secretions</a>).</p><p>Gastric distension pain due to pressure on the stomach may be helped by a preparation incorporating an antacid with an antiflatulent (<a title="target-text: Dimeticone for flatulence and hiccup" href="PHP276-antacids-and-simeticone.htm#PHP281">section 1.1.1</a>) and a prokinetic such as domperidone 10 mg 3 times daily before meals.</p></div><div><h2>Muscle spasm</h2><p>The pain of muscle spasm can be helped by a muscle relaxant such as diazepam 5–10 mg daily or baclofen 5–10 mg 3 times daily.</p></div><div id="PHP119"><h2>Neuropathic pain</h2><p>Patients with neuropathic pain (<a title="sub-section: Neuropathic pain" href="PHP2814-neuropathic-pain.htm">section 4.7.3</a>) may benefit from a trial of a tricyclic antidepressant for several weeks. An anticonvulsant may be added or substituted if pain persists; gabapentin and pregabalin (both <a title="monograph-family: Gabapentin" href="PHP2929-gabapentin-and-pregabalin.htm">section 4.8.1</a>) are licensed for neuropathic pain. Ketamine is sometimes used under specialist supervision for neuropathic pain that responds poorly to opioid analgesics.</p><p>Pain due to nerve compression may be reduced by a corticosteroid such as dexamethasone 8 mg daily, which reduces oedema around the tumour, thus reducing compression.</p><p><strong>Nerve blocks</strong> or regional anaesthesia techniques (including the use of epidural and intrathecal catheters) can be considered when pain is localised to a specific area.</p></div></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="PHP113-prescribing-in-palliative-care.htm">Previous: Prescribing in palliative care</a> | <a class="top" href="PHP114-pain.htm#">Top</a> | <a accesskey="]" href="PHP120-miscellaneous-conditions.htm">Next: Miscellaneous conditions</a> ►</div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Cookie and Privacy Policy">Cookie and Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="PHP0-publication-information.htm" rel="copyright">Copyright © BMJ Group and Pharmaceutical Press 2012. All rights reserved. </a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>